This trial, known as INTR@PID Lung 037, compared the therapeutic efficacy of M7824 with that of the PD-1-targeted ICI, pembrolizumab alone, in patients with stage IV NSCLC who had high level of expression of PD-L1 (NIH, 2021b). Here, CD274 is linked to non-small cell lung carcinoma.